Opexa Therapeutics reports net loss in Q3
Opexa’s operating loss was $1.29m, compared to $1.21m for the comparable period in 2009. For the nine months ended 30 September 2010, the company has posted a net
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
The grant was awarded under the Foundation’s Therapeutics Development Initiative aimed at supporting preclinical development of Parkinson’s disease therapies that have the potential for fundamentally altering disease course